Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00148382
Status:
COMPLETED
Last Update Posted:
2007-04-11
First Post:
2005-09-07
Brief Title:
Study of the Blood Levels and Effects of ATL-962 on Fat Excretion in Obese Subjects
Sponsor:
Alizyme
Organization:
Alizyme
Study Overview
Official Title:
Randomized Double Blind Parallel Group Repeat Dose Pharmacokinetic and Pharmacodynamic Study of Four Doses of ATL-962 40mg 80mg 120mg 240mg in Otherwise-Healthy Obese Volunteers
Status:
COMPLETED
Status Verified Date:
2007-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the amount of metabolites of ATL-962 in the blood and to investigate the effect of ATL-962 on the amount of fat that is excreted in the faeces in subjects who are obese
Detailed Description:
Obesity is a significant and increasing clinical problem There is a need for effective therapeutic agents to help people reduce weight ATL-962 is a lipase inhibitor which could reduce the amount of fat absorbed from a persons diet leading to weight reduction
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None